| P50 | author | Bettina Hansen | Q40007319 |
| | Hubert G.M. Niesters | Q44180267 |
| P2093 | author name string | Avidan U. Neumann | |
| | Solko W. Schalm | |
| | Robert A. de Man | |
| | Leonieke M.M. Wolters | |
| | Rachel S. Levi-Drummer | |
| P2860 | cites work | Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy | Q27860724 |
| | Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine | Q28367438 |
| | Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group | Q28371774 |
| | Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group | Q31405858 |
| | Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene | Q35132164 |
| | Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial | Q35359761 |
| | Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. | Q37384895 |
| | Viral dynamics in hepatitis B virus infection | Q37638400 |
| | MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs | Q40931531 |
| | A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 |
| | Dynamics of hepatitis B virus infection in vivo | Q42547404 |
| | Clinical pharmacokinetics of lamivudine | Q43755969 |
| | Viral dynamics in chronic hepatitis B patients during lamivudine therapy | Q44004765 |
| | Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy | Q45749250 |
| | Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy | Q45755644 |
| | Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. | Q52795932 |
| | Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment | Q58803469 |
| | A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group | Q68524263 |
| | Lamivudine as initial treatment for chronic hepatitis B in the United States | Q73098368 |
| | Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study | Q73760619 |
| | Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP) | Q77933591 |
| P433 | issue | 2 | |
| P921 | main subject | chronic hepatitis B | Q55779876 |
| | chronic hepatitis | Q62019625 |
| P304 | page(s) | 253-258 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine | |
| P478 | volume | 37 | |